Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Pressure is still on the pharma sector, says Mizuho's Jared Holz
07:23pm, Thursday, 08'th May 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Jury Orders Johnson & Johnson to Pay $3 Million in Mesothelioma Death of New Orleans Woman
12:07pm, Thursday, 08'th May 2025
NEW ORLEANS--(BUSINESS WIRE)--A jury has awarded $3 million to the family of Jeanine Henderson, a 72-year-old mother from New Orleans who died from mesothelioma, a rare and incurable cancer caused by
Johnson & Johnson expands efforts to champion the nursing workforce globally
08:12am, Thursday, 08'th May 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and improve access to quality care for communities around the wor
Dividend Hikes Offer Optimism Amid Tariff Turmoil
12:45am, Thursday, 08'th May 2025
Stocks have rebounded sharply off their early-April lows, but macro risks persist. Dividend stocks have largely outperformed so far this year. We profile a pair of blue chips that recently announced d
3 Stable Stocks to Buy When the Price is Right
11:25am, Tuesday, 06'th May 2025
There's no such thing as a safe stock, but these low-volatility names stand up relatively well in shaky markets.
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
10:05am, Tuesday, 06'th May 2025
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?
09:30am, Tuesday, 06'th May 2025
Both JNJ and ABBV expect their sales and profits to improve in 2025.
Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms
04:56pm, Monday, 05'th May 2025
President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S.
MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know
04:00pm, Monday, 05'th May 2025
Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
08:05am, Monday, 05'th May 2025
Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 SAN DIEGO, Calif.
TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes
2 Bulletproof Dividend Stocks to Buy in May
11:05am, Sunday, 04'th May 2025
Dividend stock investing has long been a cornerstone for building wealth, offering investors a steady stream of passive income while providing a buffer against market volatility.
3 Dividend All-Stars I'm Considering Right Now
08:36am, Sunday, 04'th May 2025
When investors think about how they want to structure their portfolios in this current environment, a few things may come to mind.
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?
04:49am, Sunday, 04'th May 2025
Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Stock market volatility or even economic downturns usually don't affect drugmakers' underlying businesses
Dogs Of The Dow Chase May's 'Safer' Buy
09:46am, Saturday, 03'rd May 2025
Verizon is the only Dow Dog meeting the ideal of annual dividends from $1K invested exceeding the single share price, supported by adequate free cash flow. Analyst projections suggest top Dow Dogs cou
